AI-powered medical imaging firm Refined Medical was awarded Section II funding in a NIH small enterprise innovation analysis (SBIR) grant to broaden its SubtleSYNTH expertise into mind imaging.
The corporate obtained FDA approval for producing artificial quick tau inversion restoration (STIR) photos (SynthSTIRs) from previously-acquired T1 and T2 weighted contrasts in spinal imaging.
Based on the corporate, the approval represents a big step ahead in MRI expertise, providing zero acquisition time for SynthSTIRs whereas preserving medical high quality comparable to traditional STIR photos.
SubtleSYNTH represents the most recent addition to the corporate’s suite of AI-driven choices, that embrace SubtleMR and SubtlePET software program.
In an announcement, the corporate mentioned SubtleSYNTH goals to enhance the effectivity and accuracy of MRI procedures, a profit to sufferers and the imaging corporations that they do enterprise with by addressing process backlogs, lengthy wait occasions and scheduling challenges.
“We’re thrilled to obtain Section II funding for the growth of our SubtleSYNTH expertise,” Ajit Shankaranarayanan, chief product officer at Refined Medical, mentioned in an announcement.
“This grant not solely validates the scientific benefit of our method but additionally empowers us to push the boundaries of what’s attainable in medical imaging. With FDA clearance for backbone imaging and the help of the NIH, we’re well-positioned to convey this transformative expertise to mind imaging, additional enhancing the pace, high quality and security of MRI exams.”
THE LARGER TREND
On July 24, Refined Medical raised near $10 million in a Collection B+ spherical, bringing its Collection B increase to over $30 million and whole financing to greater than $50 million.
The funds had been used to speed up U.S. and world gross sales initiatives and expedite the launch of latest AI-driven merchandise.
SubtleSYNTH compliments the corporate’s beforehand FDA-cleared SubtleMR software program, which permits accelerated picture acquisition of as much as 60 p.c for MRI procedures on any vendor’s product.
The HIMSS Healthcare Cybersecurity Discussion board is scheduled to happen October 31-November 1 in Washington, D.C.